key: cord-0889647-elimnt4y
authors: Gao, Qianqian; Liu, Shang; Ding, Renpeng; Chen, Huanyi; Dong, Xuan; Xie, Jiarui; Li, Yijian; Chen, Lei; Liu, Huan; Mu, Feng
title: The expression of PDCD1 and CD274 in T cells and macrophages correlated positively with COVID-19 severity
date: 2020-11-18
journal: bioRxiv
DOI: 10.1101/2020.11.17.378992
sha: 5cc39edf0c241be85b3c0f143e0446020d43ab04
doc_id: 889647
cord_uid: elimnt4y

The immune responses underlying the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain unclear. To help understand the pathology of coronavirus disease 2019 (COVID-19) pandemics, public data were analyzed and the expression of PDCD1 (encoding PD-1) and CD274 (encoding PD-L1) in T cells and macrophages were identified to correlate positively with COVID-19 severity.

COVID-19 has led to the global pandemic and infected millions of people worldwide [1]. It's urgent to better understand the pathophysiology of the infection caused by SARS-CoV-2 [2] [3] [4] . The PD-1/PD-L1 signaling plays an essential role not only in regulating tumor immune responses but also in balancing homeostasis and tolerance in virus infection [5] , but it's role in COVID-19 is currently unclear. Thus, it is necessary to investigate how PD-1/PD-L1 signaling works during progress in order to deal with it.

Single-cell immune profiling was explored in COVID-19 patients using the public data, which is essential for understanding the potential mechanisms underlying COVID-19 pathogenesis.

We downloaded the gene expression matrix from GEO database (GSE145926 and GSE128033).

This dataset contained 63734 cells from four healthy people, three patients with moderate infection by bilateral pneumonia and seven patients with severe infection. The detailed clinical information of patients can be obtained in the reference [6] . Single cell clustering and cell annotation was performed as previously described [6] .

The Student's t-test (t.test in R 3.5.1) was used across three experiment designs. *P<0.05, **P<0.005, ***P ＜ 0.001. Values are presented as mean Standard deviation (SD). Error bars represented the SD.

Publicly available data of bronchoalveolar cells from three moderate (M1-M3) and six severe (S1-S6) COVID-19 patients, and four healthy controls (HC1-HC4) were collected for analysis (66630 cells, Table S1 ) [6] . 31 clusters were identified by classical signature genes according to the reference ( Fig. 1) [6] . CD68-Macrophage (0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 15, 19, 21, 24, 30) dominated among these populations, followed by CD3D-T cell (4, 10, 16) .

Expression of PDCD1 was first analyzed at the patient group level in different cell subpopulations, and four trends of their expression dynamics were observed (Fig. 2) . PDCD1 expression was gradually elevated in T cell, B cell, myeloid dendritic cells (mDCs), and macrophages from HC to mild cases then to severe patients ( Fig. 2A) . In the 2 nd trend, PDCD1 expression was specifically increased in plasma cells and epithelial cells in severe patients but not in mild patients (Fig. 2B ).

For the 3 rd trend, PDCD1 expression was upregulated in mild patients but slightly reduced in severe patients in NK and plasmacytoid dendritic cells (pDCs) (Fig. 2C ). No expression of PDCD1 was detected in mast cells and neutrophils in the 4 th trend (Fig. 2D ).

The CD274 expression in macrophages, mast cells, pDC, and T cells (1 st trend) correlated well with COVID-19 severity (Fig. 3A) and was specifically increased in plasma cells of severe patients (2 nd trend) (Fig. 3B ). However, in neutrophil, mDC, B cells and NK cells, the expression of CD274 was upregulated in patients with mild COVID-19, then decreased in severe patients (Fig. 3C ). In contrary to the 3 rd trend, the expression of CD274 was decreased in mild patients but increased in severe patients ( Fig. 3D ). When analyzed at the individual level, expression of PDCD1 and CD274 was also elevated in mild and severe patients (Fig. 4A, 4B ). Overall, PDCD1 expression in T cells, B cells, mDCs, and macrophages and CD274 expression in macrophages, mast cells, pDC, and T cells correlated well with COVID-19 severity. Furthermore, PDCD1 and CD274 expression was specifically increased in epithelial and plasma cells of severe patients.

Inflammatory signaling participates in modulating PD-L1 expression, particularly, STAT1, which can be activated by IFNγ or interleukin 6 (IL-6), is a crucial regulator for PD-L1 expression [7, 8] .

Furthermore, plasma IFNγ level [3] and the IL-6 level in bronchoalveolar lavage fluid (BALF) [6] were reported to be increased in COVID-19 patients. Consistently, STAT1 was found upregulated in both mild and severe patients (Fig. 5) , suggesting increased CD274 expression might at least partly resulting from increased STAT1 level in COVID-19 patients. and CD40 were highest in severe patients (Fig. 6B) .

When analyzed at the cell subpopulation level, unique expression patterns of ICMs and SCMs were demonstrated in each cell subpopulation (Fig. 7, Fig. 8 ). Expression patterns of ICMs were different between mild and severe patients (Fig. 7) . Most categories and the highest intensity of ICMs were enriched in severe patients, except in T cells and NK cells. The results indicated that the immune cells might be more exhausted in severe patients with COVID-19 compared to healthy people and even mild patients. In terms of SCMs, macrophages, mast cells, and pDC of severe patients got more enriched than that of mild patients and healthy donors (Fig. 8) . In T cell population, more ICMs and SCMs were enriched in patients with mild and severe COVID-19 than that of healthy donors, but there was no dramatic difference between mild and severe patients themselves (Fig. 7,   Fig. 8 ).

Since COVID-19 is pandemic and threatening thousands of people's life, it is urgent and essential to investigate the molecular mechanism of the immune pathogenesis of the disease. Compared to healthy controls, PDCD1 expression in T cells, B cells, mDCs, and macrophages (Fig. 2) and CD274 expression in macrophages, mast cells, pDCs, and T cells (Fig. 3) were upregulated in COVID-19 patients, and correlated well with COVID-19 severity. Moreover, expression of PDCD1 and CD274 was specifically increased in plasma cells of severe patients (Fig. 2, 3) , which could serve as a biomarker for prognosing the severity of COVID-19. Many clinical trials for treating COVID-19 are ongoing. Among them, one clinical trial uses PD-1 monoclonal antibody to block PD-1 in COVID-19 patients (NCT04268537). Based on our results, PDCD1 expression was dramatically upregulated in T cells and macrophages especially in severe patients (Fig. 2) and its blockade would further increase the secretion of multiple pro-inflammatory cytokines, which will enhance the cytokine release syndrome reported in COVID-19 patients and possibly associated with disease severity [2, 3] , leading to further tissue damage or even more death especially in severe COVID-19 patients [9, 10] . A current study supports that checkpoint inhibitor immunotherapy is risky for severe outcomes in SARS-CoV-2-infected cancer patients, though these patients were treated with immune checkpoint inhibitors (ICI) before SARS-CoV-2 infection [11] .

Our research provides valuable information about COVID-19 and its severity correlated well with the expression of PDCD1 and CD274.

The authors declare that they have no competing interests.

Gao Q. supervised the project, designed the bioinformatic analysis, wrote and revised the manuscript. Liu S. performed the bioinformatic analysis. Ding R. dealt with the data. Chen H., Dong X., Xie J., Li Y., Chen L., and Liu H. helped with the data management. 

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

IFNgamma induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Determinants of COVID-19 disease severity in patients with cancer

We sincerely thank the support provided by China National GeneBank and this research was